{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:17:03Z","timestamp":1790047023366,"version":"4.0.1"},"reference-count":137,"publisher":"Japan Atherosclerosis Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.5551\/jat.65908","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T22:07:50Z","timestamp":1766354870000},"page":"336-364","source":"Crossref","is-referenced-by-count":5,"title":["Lipid Management for Secondary Prevention in Atherosclerotic Cardiovascular Disease: A Scoping Review and Scientific Report"],"prefix":"10.5551","volume":"33","author":[{"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yakushiji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kansai Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Natsuaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, St Luke'fs International Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamagami","sequence":"additional","affiliation":[{"name":"Division of Stroke Prevention and Treatment, Institute of Medicine, University of Tsukuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenobu","family":"Kunieda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kansai Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Shibata","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology & Hypertension, International University of Health and Welfare Mita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Ayuzawa","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Shimabukuro","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichiro","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, University of Yamanashi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okazaki","sequence":"additional","affiliation":[{"name":"The Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo"},{"name":"Department of Advanced Cardiology, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Life Science and Bioethics Research Center, Institute of Science Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Shimano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-e1143","DOI":"10.1161\/CIR.0000000000000624"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Writing Committee; Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr, Waring AA, Wilkins JT: 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol, 2022; 80: 1366-1418","DOI":"10.1016\/j.jacc.2022.07.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kaplan H, Thompson RC, Trumble BC, Wann LS, Allam AH, Beheim B, Frohlich B, Sutherland ML, Sutherland JD, Stieglitz J, Rodriguez DE, Michalik DE, Rowan CJ, Lombardi GP, Bedi R, Garcia AR, Min JK, Narula J, Finch CE, Gurven M, Thomas GS: Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. Lancet, 2017; 389: 1730-1739","DOI":"10.1016\/S0140-6736(17)30752-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A, Yanai H: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853","DOI":"10.5551\/jat.GL2022"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Honda T, Chen S, Hata J, Yoshida D, Hirakawa Y, Furuta Y, Shibata M, Sakata S, Kitazono T, Ninomiya T: Development and validation of a risk prediction model for atherosclerotic cardiovascular disease in Japanese adults: The Hisayama Study. J Atheroscler Thromb, 2022; 29: 345-361","DOI":"10.5551\/jat.61960"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Inohara T, Kohsaka S, Goto M, Furukawa Y, Fukushima M, Sakata R, Elayda M, Wilson JM, Kimura T: Hypothesis of Long-Term Outcome after Coronary Revascularization in Japanese Patients Compared to Multiethnic Groups in the US. PLoS One, 2015; 10: e0128252","DOI":"10.1371\/journal.pone.0128252"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nguyen PK, Zhao D, Okamura T, Chang Kim H, Wong ND, Yang E: Atherosclerotic Cardiovascular Disease Risk Prediction Models in China, Japan, and Korea: Implications for East Asians? JACC Asia, 2025; 5(3 Pt 1): 333-349","DOI":"10.1016\/j.jacasi.2025.01.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kitamura A, Sato S, Kiyama M, Imano H, Iso H, Okada T, Ohira T, Tanigawa T, Yamagishi K, Nakamura M, Konishi M, Shimamoto T, Iida M, Komachi Y: Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. J Am Coll Cardiol, 2008; 52: 71-79","DOI":"10.1016\/j.jacc.2008.02.075"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, Lu C, Tay L, Deedwania PC, Siu CW, Lira Pineda A, Choi D, Charng MJ, Amerena J, Wan Ahmad WA, Chopra VK, Pedersen TR, Giugliano RP, Sabatine MS; FOURIER Study Group: Efficacy and safety of long-term evolocumab use among Asian subjects - a subgroup analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. Circ J, 2021; 85: 2063-2070","DOI":"10.1253\/circj.CJ-20-1051"},{"key":"11","unstructured":"11) Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, J\u00fcni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group: 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J, 2023; 44: 3720-3826"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nakano S, Kohsaka S, Chikamori T, Fukushima K, Kobayashi Y, Kozuma K, Manabe S, Matsuo H, Nakamura M, Ohno T, Sawano M, Toda K, Ueda Y, Yokoi H, Gatate Y, Kasai T, Kawase Y, Matsumoto N, Mori H, Nakazato R, Niimi N, Saito Y, Shintani A, Watanabe I, Watanabe Y, Ikari Y, Jinzaki M, Kosuge M, Nakajima K, Kimura T; JCS Joint Working Group: JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease. Circ J, 2022; 86: 882-915","DOI":"10.1253\/circj.CJ-21-1041"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, Ferreira J, Kurtz CE, Wang H, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP: Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER Trial. JAMA Cardiol, 2020; 5: 952-957","DOI":"10.1001\/jamacardio.2020.0882"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL, de Lemos JA, DeWald TA, Elgendy IY, Feldman DN, Goyal A, Isiadinso I, Menon V, Morrow DA, Mukherjee D, Platz E, Promes SB, Sandner S, Sandoval Y, Schunder R, Shah B, Stopyra JP, Talbot AW, Taub PR, Williams MS: 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2025; 151: e771-e862","DOI":"10.1161\/CIR.0000000000001346"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 1993; 24: 35-41","DOI":"10.1161\/01.STR.24.1.35"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nair R, Johnson M, Kravitz K, Huded C, Rajeswaran J, Anabila M, Blackstone E, Menon V, Lincoff AM, Kapadia S, Khot UN: Characteristics and outcomes of early recurrent myocardial infarction after acute myocardial infarction. J Am Heart Assoc, 2021; 10: e019270","DOI":"10.1161\/JAHA.120.019270"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Lee SH, Jeong MH, Ahn JH, Hyun DY, Cho KH, Kim MC, Sim DS, Hong YJ, Kim JH, Ahn Y, Hwang JY, Kim W, Park JS, Yoon CH, Hur SH, Lee SR, Cha KS; KAMIR (Korea Acute Myocardial Infarction Registry)-NIH Investigators: Predictors of recurrent acute myocardial infarction despite successful percutaneous coronary intervention. Korean J Intern Med, 2022; 37: 777-785","DOI":"10.3904\/kjim.2021.427"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Daida H, Miyauchi K, Hisao Ogawa, Hiroyoshi Yokoi, Masayasu Matsumoto, Masafumi Kitakaze, Takeshi Kimura, Tetsuo Matsubara, Yuji Ikari, Kazuo Kimura, Kengo Tsukahara, Hideki Origasa, Yoshihiro Morino, Hiroyuki Tsutsui, Masayuki Kobayashi, Takaaki Isshiki; PACIFIC investigators: Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J, 2013; 77: 934-943","DOI":"10.1253\/circj.CJ-13-0174"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG: Early, intensive statin treatment reduces \u2018hard\u2019 cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol, 2017; 24: 1294-1296","DOI":"10.1177\/2047487317708677"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Yu S, Jin J, Chen Z, Luo X: High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis, 2020; 19: 194","DOI":"10.1186\/s12944-020-01369-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Natsuaki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, Inada T, Mitsuoka H, Taniguchi R, Nakano A, Kita T, Sakata R, Kimura T; CREDO-Kyoto PCI\/CABG registry cohort-2 investigators: Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. Circ J, 2012; 76: 1369-1379","DOI":"10.1253\/circj.CJ-11-1356"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, Gorny B, Wirianta J, Kubica J, Kelm M, de Boer MJ, Suryapranata H: Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol, 2014; 113: 1753-1764","DOI":"10.1016\/j.amjcard.2014.02.034"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, Kojima T, Yokoyama K, Kurata T, Daida H: Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis, 2010; 210: 497-502","DOI":"10.1016\/j.atherosclerosis.2009.12.001"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Okada K, Haze T, Kikuchi S, Kirigaya H, Hanajima Y, Tsutsumi K, Kirigaya J, Nakahashi H, Gohbara M, Kimura Y, Kosuge M, Ebina T, Sugano T, Hibi K: Early, Intensive and Persistent Lipid-Lowering Therapy for Secondary Prevention of Acute Coronary Syndrome. J Atheroscler Thromb, 2024; 31: 1748-1762","DOI":"10.5551\/jat.64988"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Mahajan K, Nagendra L, Dhall A, Dutta D: Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis. Eur J Intern Med, 2024; 124: 99-107","DOI":"10.1016\/j.ejim.2024.02.004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hosseini K, Soleimani H, Maleki S, Nasrollahizadeh A, Tayebi S, Nelson J, Heffron SP: Early administration of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Cardiovasc Disord, 2024; 24: 395","DOI":"10.1186\/s12872-024-04057-w"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K, Kurpas D, Niessner A, Schiele F, Semb AG, Sionis A, Claeys MJ, Barrabes J, Montero S, Sinnaeve P, Pedretti R, Catapano A: Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Acute Cardiovasc Care, 2022; 11: 939-949","DOI":"10.1093\/ehjacc\/zuac123"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J: Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review. J Am Coll Cardiol, 2022; 79: 66-82","DOI":"10.1016\/j.jacc.2021.10.035"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Nishiguchi T, Kubo T, Tanimoto T, Ino Y, Matsuo Y, Yamano T, Terada K, Emori H, Katayama Y, Taruya A, Ozaki Y, Shiono Y, Shimamura K, Kameyama T, Kitabata H, Yamaguchi T, Tanaka A, Hozumi T, Akasaka T: Effect of early pitavastatin therapy on coronary fibrous-cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome: The ESCORT Study. JACC Cardiovasc Imaging, 2018; 11: 829-838","DOI":"10.1016\/j.jcmg.2017.07.011"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Hirai K, Kawasaki T, Soejima T, Kajiyama K, Fukami Y, Asada S, Haraguchi K, Fukuoka R, Orita Y, Umeji K, Koga H, Yamabe H: Impact of intensive low-density lipoprotein cholesterol-lowering therapy on coronary artery plaques in acute coronary syndrome. Am J Cardiol, 2023; 204: 84-91","DOI":"10.1016\/j.amjcard.2023.07.049"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H; PRECISE\u2013IVUS Investigators: Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS Trial. J Am Coll Cardiol, 2015; 66: 495-507","DOI":"10.1016\/j.jacc.2015.05.065"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Hibi K, Sonoda S, Kawasaki M, Otsuji Y, Murohara T, Ishii H, Sato K, Koshida R, Ozaki Y, Sata M, Morino Y, Miyamoto T, Amano T, Morita S, Kozuma K, Kimura K, Fujiwara H; Ezetimibe-ACS Investigators: Effects of ezetimibe-statin combination therapy on coronary atherosclerosis in acute coronary syndrome. Circ J, 2018; 82: 757-766","DOI":"10.1253\/circj.CJ-17-0598"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Mirzaee S, Thein PM, Nogic J, Nerlekar N, Nasis A, Brown AJ: The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis. J Clin Lipidol, 2018; 12: 1133-1140.e15","DOI":"10.1016\/j.jacl.2018.06.001"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE: Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV Randomized Clinical Trial. JAMA, 2016; 316: 2373-2384","DOI":"10.1001\/jama.2016.16951"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JR, Hermanides RS, Wang B, Wang H, Butters J, Di Giovanni G, Jones S, Pompili G, Psaltis PJ: Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging, 2022; 15: 1308-1321","DOI":"10.1016\/j.jcmg.2022.03.002"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) R\u00e4ber L, Ueki Y, Otsuka T, Losdat S, H\u00e4ner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, Radu Juul Jensen MD, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstr\u00f8m T, Lang IM, Koskinas KC; PACMAN-AMI collaborators: Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA, 2022; 327: 1771-1781","DOI":"10.1001\/jama.2022.5218"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Yano H, Horinaka S, Ishimitsu T: Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J Cardiol, 2020; 75: 289-295","DOI":"10.1016\/j.jjcc.2019.08.002"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Uehara H, Kajiya T, Abe M, Nakata M, Hosogi S, Ueda S: Early and short-term use of proprotein convertase anti-subtilisin-kexin type 9 inhibitors on coronary plaque stability in acute coronary syndrome. Eur Heart J Open, 2024; 4: oeae055","DOI":"10.1093\/ehjopen\/oeae055"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Liu S, Wang P, Liu C, Jin M, Wan J, Hou J, Yang Y, Wang D, Liu Z, Fu Z: Effect of PCSK9 antibodies on coronary plaque regression and stabilization derived from intravascular imaging in patients with coronary artery disease: A meta-analysis. Int J Cardiol, 2023; 392: 131330","DOI":"10.1016\/j.ijcard.2023.131330"},{"key":"41","unstructured":"41) Wu Z, Gao L, Lin Z: Can proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors regress coronary atherosclerotic plaque? A systematic review and meta-analysis. Am J Transl Res, 2023; 15: 452-465"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Iatan I, Guan M, Humphries KH, Yeoh E, Mancini GBJ: Atherosclerotic coronary plaque regression and risk of adverse cardiovascular events: a systematic review and updated meta-regression analysis. JAMA Cardiol, 2023; 8: 937-945","DOI":"10.1001\/jamacardio.2023.2731"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Mitani H, Suzuki K, Ako J, Iekushi K, Majewska R, Touzeni S, Yamashita S: Achievement rates for low-density lipoprotein cholesterol goals in patients at high risk of atherosclerotic cardiovascular disease in a real-world setting in Japan. J Atheroscler Thromb, 2023; 30: 1622-1634","DOI":"10.5551\/jat.63940"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Nakamura M, Ako J, Arai H, Hirayama A, Nohara A, Murakami Y, Ozaki A, Harada-Shiba M: Lipid management and 2-year clinical outcomes in Japanese patients with acute coronary syndrome: EXPLORE-J. J Atheroscler Thromb, 2021; 28: 1307-1322","DOI":"10.5551\/jat.59543"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Nakahashi T, Tada H, Sakata K, Yakuta Y, Tanaka Y, Nomura A, Gamou T, Terai H, Horita Y, Ikeda M, Namura M, Takamura M, Hayashi K, Yamagishi M, Kawashiri MA: Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome. Heart Vessels, 2018; 33: 695-705","DOI":"10.1007\/s00380-017-1111-3"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Oyama K, Giugliano RP, Blazing MA, Park JG, Tershakovec AM, Sabatine MS, Cannon CP, Braunwald E: Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol, 2021; 78: 1499-1507","DOI":"10.1016\/j.jacc.2021.08.011"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Gargiulo P, Basile C, Galasso G, Bellino M, D\u2019Elia D, Patti G, Bosco M, Prinetti M, And\u00f2 G, Campanella F, Taverna G, Calabr\u00f2 P, Cesaro A, Fimiani F, Catalano A, Varbella F, Corleto A, Barill\u00e0 F, Muscoli S, Musumeci G, Delnevo F, Giallauria F, Napoli R, Porto I, Polimeni A, Quarta R, Maloberti A, Merlini PA, De Luca L, Casu G, Brunetti ND, Crisci M, Paloscia L, Bilato C, Indolfi C, Marzano F, Fontanarosa S, Buonocore D, Parlati ALM, Nardi E, Prastaro M, Soricelli A, Salvatore M, Paolillo S, Perrone-Filardi P, Cuomo G, Testa C, Passaretti G, Vallefuoco G, Romano A, Dell\u2019Anno R, Merolla A, Iannone FP: Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry. Eur J Prev Cardiol, 2024; 31: 1806-1816","DOI":"10.1093\/eurjpc\/zwae170"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators: Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, 2017; 390: 1962-1971","DOI":"10.1016\/S0140-6736(17)32290-0"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS: Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA Cardiol, 2017; 2: 1385-1391","DOI":"10.1001\/jamacardio.2017.3944"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR: Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER. Circulation, 2018; 138: 756-766","DOI":"10.1161\/CIRCULATIONAHA.118.034309"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Gaba P, O\u2019Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Flores-Arredondo JH, L\u00f3pez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Giugliano RP, Sabatine MS: Association Between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation, 2023; 147: 1192-1203","DOI":"10.1161\/CIRCULATIONAHA.122.063399"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Hirayama A, Yamashita S, Inomata H, Kassahun H, Cyrille M, Ruzza A, Yoshida M, Kiyosue A, Ma Y, Teramoto T: One-Year Efficacy and Safety of Evolocumab in Japanese Patients - A Pooled Analysis From the Open-Label Extension OSLER Studies. Circ J, 2017; 81: 1029-1035","DOI":"10.1253\/circj.CJ-16-1016"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Hirayama A, Yamashita S, Ruzza A, Inomata H, Cyrille M, Lu C, Hamer AW, Yoshida M, Kiyosue A, Teramoto T: Long-term treatment with evolocumab among Japanese patients - final report of the OSLER Open-Label Extension Studies. Circ J, 2019; 83: 971-977","DOI":"10.1253\/circj.CJ-19-0139"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators: Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med, 2020; 382: 1507-1519","DOI":"10.1056\/NEJMoa1912387"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Huo Y, Lesogor A, Lee CW, Chiang CE, Mena-Madrazo J, Poh KK, Jeong MH, Maheux P, Zhang M, Wei S, Han Y, Li Y: Efficacy and safety of inclisiran in Asian Patients: Results from ORION-18. JACC Asia, 2023; 4: 123-134","DOI":"10.1016\/j.jacasi.2023.09.006"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS; ORION Phase III investigators: Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J, 2023; 44: 129-138","DOI":"10.1093\/eurheartj\/ehac594"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS; Peer Review Committee Members: 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 2023; 148: e9-e119","DOI":"10.1161\/CIR.0000000000001168"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Koh N, Ference BA, Nicholls SJ, Navar AM, Chew DP, Kostner K, He B, Tse HF, Dalal J, Santoso A, Ako J, Tada H, Park JJ, Ong ML, Lim E, Subramaniam T, Li YH, Phrommintikul A, Iyengar SS, Ray S, Park KW, Tan HC, Chunhamaneewat N, Yeo KK, Tan JWC: Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. Eur Cardiol, 2021; 16: e54","DOI":"10.15420\/ecr.2021.36"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Cholesterol Treatment Trialists\u2019 (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Cholesterol Treatment Trialists\u2019 (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012; 380: 581-590","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R: High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): A randomized superiority trial. Circulation, 2018; 137: 1997-2009","DOI":"10.1161\/CIRCULATIONAHA.117.032615"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Sakuma M, Iimuro S, Shinozaki T, Kimura T, Nakagawa Y, Ozaki Y, Iwata H, Miyauchi K, Daida H, Suwa S, Sakuma I, Nishihata Y, Saito Y, Ogawa H, Matsuzaki M, Ohashi Y, Taguchi I, Toyoda S, Inoue T, Nagai R: Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. BMC Med, 2022; 20: 441","DOI":"10.1186\/s12916-022-02633-5"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Eisen A, Cannon CP, Blazing MA, Bohula EA, Park JG, Murphy SA, White JA, Giugliano RP, Braunwald E; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators: The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J, 2016; 37: 3576-3584","DOI":"10.1093\/eurheartj\/ehw377"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Perak AM, Ning H, de Ferranti SD, Gooding HC, Wilkins JT, Lloyd-Jones DM: Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. Circulation, 2016; 134: 9-19","DOI":"10.1161\/CIRCULATIONAHA.116.022335"},{"key":"67","unstructured":"67) Ferri\u00e8res J, Farnier M, Bruckert E, Vimont A, Durlach V, Ferrari E, Gallo A, Boccara F, Ferri\u00e8res D, B\u00e9liard S; French FH Registry group: French REgistry of Familial hypERCHOLesterolemia (REFERCHOL): Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia. Atheroscler Plus, 2022; 50: 17-24"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) P\u00e9rez de Isla L, Alonso R, Mata N, Saltijeral A, Mu\u00f1iz O, Rubio-Marin P, Diaz-Diaz JL, Fuentes F, de Andr\u00e9s R, Zamb\u00f3n D, Galiana J, Piedecausa M, Aguado R, Mosquera D, Vidal JI, Ruiz E, Manj\u00f3n L, Mauri M, Padr\u00f3 T, Miramontes JP, Mata P; SAFEHEART Investigators: Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol, 2016; 36: 2004-2010","DOI":"10.1161\/ATVBAHA.116.307514"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Yamashita S, Masuda D, Harada-Shiba M, Arai H, Bujo H, Ishibashi S, Daida H, Koga N, Oikawa S: effectiveness and safety of lipid-lowering drug treatments in Japanese patients with familial hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J Atheroscler Thromb, 2022; 29: 608-638","DOI":"10.5551\/jat.62764"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Funabashi S, Kataoka Y, Hori M, Ogura M, Doi T, Morita Y, Kiyoshige E, Nishimura K, Noguchi T, Harada-Shiba M: asymptomatic intracranial artery stenosis\/occlusion in heterozygous familial hypercholesterolemia: its frequency and implications for cerebrovascular and cardiovascular events. J Am Heart Assoc, 2024; 13: e033972","DOI":"10.1161\/JAHA.123.033972"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Yu Y, Chen L, Zhang H, Fu Z, Liu Q, Zhao H, Liu Y, Chen Y: Association between familial hypercholesterolemia and risk of cardiovascular events and death in different cohorts: a meta-analysis of 1.1 million subjects. Front Cardiovasc Med, 2022; 9: 860196","DOI":"10.3389\/fcvm.2022.860196"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Ghasempour G, Zamani-Garmsiri F, Shaikhnia F, Soleimani AA, Hosseini Fard SR, Leila J, Teimuri S, Parvaz N, Mohammadi P, Najafi M: Efficacy and safety of alirocumab and evolocumab as proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in familial hypercholesterolemia: a systematic review and meta-analysis. Curr Med Chem, 2024; 31: 223-241","DOI":"10.2174\/0929867330666230228120601"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Yokote K, Ako J, Kitagawa K, Osada N, Sheng F, Sonoda M, Teramoto T: Safety and effectiveness of low-density lipoprotein cholesterol-lowering therapy with evolocumab for familial hypercholesterolemia\/hypercholesterolemia in Japan: A real-world, postmarketing, single-arm study. J Am Heart Assoc, 2024; 13: e035809","DOI":"10.1161\/JAHA.124.035809"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal\u00e1n R, \u0160pinar J, Park JG, White JA, Bohula EA, Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators: Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 2018; 137: 1571-1582","DOI":"10.1161\/CIRCULATIONAHA.117.030950"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, Gill JS, Hlatky MA, Jardine AG, Landmesser U, Newby LK, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, Marwick TH; Conference Participants: Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol, 2019; 74: 1823-1838","DOI":"10.1016\/j.jacc.2019.08.1017"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Higuma T, Akashi YJ, Fukumoto Y, Obara H, Kakuma T, Asaumi Y, Yasuda S, Sakuma I, Daida H, Shimokawa H, Kimura T, Iimuro S, Nagai R: Residual coronary risk factors associated with long-term clinical outcomes in patients with coronary artery disease treated with high- vs. low-dose statin therapy- REAL-CAD Substudy. Circ J, 2024; 88: 995-1003","DOI":"10.1253\/circj.CJ-23-0134"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Wakabayashi K, Suzuki H, Fukumoto Y, Obara H, Kakuma T, Sakuma I, Kimura T, Iimuro S, Daida H, Shimokawa H, Nagai R: Comorbidities associated with residual cardiovascular risk in patients with chronic coronary syndrome receiving statin therapy- subanalysis of the REAL-CAD Trial. Circ Rep, 2022; 4: 422-428","DOI":"10.1253\/circrep.CR-22-0070"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP; FOURIER Steering Committee and Investigators: Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER Trial. J Am Coll Cardiol, 2019; 73: 2961-2970","DOI":"10.1016\/j.jacc.2019.03.513"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Hubbard D, Colantonio LD, Rosenson RS, Brown TM, Jackson EA, Huang L, Orroth KK, Reading S, Woodward M, Bittner V, Gutierrez OM, Safford MM, Farkouh ME, Muntner P: Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease. Cardiovasc Diabetol, 2021; 20: 58","DOI":"10.1186\/s12933-021-01247-0"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Bohula EA, Marston NA, Ruzza A, Murphy SA, De Ferrari GM, Diaz R, Leiter LA, Elliott-Davey M, Wang H, Bhatia AK, Giugliano RP, Sabatine MS: Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. Am Heart J, 2024; 269: 179-190","DOI":"10.1016\/j.ahj.2023.12.004"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Steg PG, Bhatt DL, Wilson PW, D\u2019Agostino R Sr, Ohman EM, R\u00f6ther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators: One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA, 2007; 297: 1197-1206","DOI":"10.1001\/jama.297.11.1197"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Uchiyama S, Goto S, Matsumoto M, Nagai R, Origasa H, Yamazaki T, Shigematsu H, Shimada K, Yamada N, Bhatt DL, Steg PG, Ikeda Y; REduction of Atherothrombosis for Continued Health Registry Investigators: Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry. J Neurol Sci, 2009; 287: 45-51","DOI":"10.1016\/j.jns.2009.09.011"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS: Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation, 2018; 137: 338-350","DOI":"10.1161\/CIRCULATIONAHA.117.032235"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, Ruzza A, Keech AC, Sever PS, Sabatine MS, Bergmark BA: Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial. Eur Heart J, 2021; 42: 4821-4829","DOI":"10.1093\/eurheartj\/ehab604"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators: Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol, 2019; 74: 1167-1176","DOI":"10.1016\/j.jacc.2019.03.013"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald E: Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol, 2018; 6: 934-943","DOI":"10.1016\/S2213-8587(18)30290-0"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith SC Jr, Turan TN, Williams LS: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association. Stroke, 2021; 52: e364-e467","DOI":"10.1161\/STR.0000000000000375"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Hata J, Ninomiya T: Epidemiology of stroke in a general Japanese population: The Hisayama Study. J Atheroscler Thromb, 2023; 30: 710-719","DOI":"10.5551\/jat.RV22004"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Gunnoo T, Hasan N, Khan MS, Slark J, Bentley P, Sharma P: Quantifying the risk of heart disease following acute ischaemic stroke: a meta-analysis of over 50,000 participants. BMJ Open, 2016; 6: e009535","DOI":"10.1136\/bmjopen-2015-009535"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Hoshino A, Nakamura T, Enomoto S, Kawahito H, Kurata H, Nakahara Y, Ijichi T: Prevalence of coronary artery disease in Japanese patients with cerebral infarction: impact of metabolic syndrome and intracranial large artery atherosclerosis. Circ J, 2008; 72: 404-408","DOI":"10.1253\/circj.72.404"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Enomoto Y, Yoshimura S, Yamada K, Kawasaki M, Nishigaki K, Minatoguchi S, Iwama T: Silent coronary artery disease in Japanese patients undergoing carotid artery stenting. J Stroke Cerebrovasc Dis, 2013; 22: 1163-1168","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.013"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Psychogios M, Brehm A, L\u00f3pez-Cancio E, Marco De Marchis G, Meseguer E, Katsanos AH, Kremer C, Sporns P, Zedde M, Kobayashi A, Caroff J, Bos D, L\u00e9meret S, Lal A, Arenillas JF: European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease. Eur Stroke J, 2022; 7: III-IV","DOI":"10.1177\/23969873221099715"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Miyamoto S, Ogasawara K, Kuroda S, Itabashi R, Toyoda K, Itoh Y, Iguchi Y, Shiokawa Y, Takagi Y, Ohtsuki T, Kinouchi H, Okada Y, Takahashi JC, Nakase H, Kakuda W; Committee for Stroke Guideline 2021, the Japan Stroke Society: Japan Stroke Society Guideline 2021 for the Treatment of Stroke. Int J Stroke, 2022; 17: 1039-1049","DOI":"10.1177\/17474930221090347"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Yin Y, Zhang L, Marshall I, Wolfe C, Wang Y: Statin therapy for preventing recurrent stroke in patients with ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and observational cohort studies. Neuroepidemiology, 2022; 56: 240-249","DOI":"10.1159\/000525672"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Ziff OJ, Banerjee G, Ambler G, Werring DJ: Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry, 2019; 90: 75-83","DOI":"10.1136\/jnnp-2018-318483"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, Maruyama H, Sunami N, Yokota C, Kitagawa K, Terayama Y, Takagi M, Ibayashi S, Nakamura M, Origasa H, Fukushima M, Mori E, Minematsu K, Uchiyama S, Shinohara Y, Yamaguchi T, Matsumoto M; J-STARS Collaborators: The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A multicenter, randomized, open-label, parallel-group study. EBioMedicine, 2015; 2: 1071-1078","DOI":"10.1016\/j.ebiom.2015.08.006"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Hosomi N, Kitagawa K, Nagai Y, Nakagawa Y, Aoki S, Nezu T, Kagimura T, Maruyama H, Origasa H, Minematsu K, Uchiyama S, Matsumoto M; J-STARS Collaborators: Desirable low-density lipoprotein cholesterol levels for preventing stroke recurrence: a post hoc analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke). Stroke, 2018; 49: 865-871","DOI":"10.1161\/STROKEAHA.117.018870"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, B\u00e9jot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B, Lavall\u00e9e PC, Lee BC, Lee KB, Leys D, Mahagne MH, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg PG, Sung SM, Touboul PJ, Touz\u00e9 E, Varenne O, Vicaut \u00c9, Yelles N, Bruckert E; Treat Stroke to Target Investigators: A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med, 2020; 382: 9","DOI":"10.1056\/NEJMoa1910355"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lee BC, Lavall\u00e9e PC, Mahagne MH, Meseguer E, Nighoghossian N, Steg PG, Vicaut \u00c9, Bruckert E; Treat Stroke to Target Investigators: Yield of dual therapy with statin and ezetimibe in the Treat Stroke to Target Trial. Stroke, 2022; 53: 3260-3267","DOI":"10.1161\/STROKEAHA.122.039728"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lavall\u00e9e PC, Lee BC, Mahagne MH, Meseguer E, Nighoghossian N, Steg PG, Vicaut \u00c9, Bruckert E; Treat Stroke to Target Investigators*: Intracranial hemorrhage in the TST Trial. Stroke, 2022; 53: 457-462","DOI":"10.1161\/STROKEAHA.122.039728"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, Murphy SA, Wasserman SM, Honarpour N, Wang H, Lira Pineda A, Sabatine MS; FOURIER Investigators: Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9)inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke, 2020; 51: 1546-1554","DOI":"10.1161\/STROKEAHA.119.027759"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf F, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E: Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 2017; 136: 2440-2450","DOI":"10.1161\/CIRCULATIONAHA.117.029095"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner \u017d, Roe MT, Tse HF, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Investigators: Effect of alirocumab on stroke in ODYSSEY OUTCOMES. Circulation, 2019; 140: 2054-2062","DOI":"10.1161\/CIRCULATIONAHA.119.043826"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Li J, Imano H, Kitamura A, Kiyama M, Yamagishi K, Tanaka M, Ohira T, Sankai T, Umesawa M, Muraki I, Hayama-Terada M, Cui R, Shimizu Y, Okada T, Sato S, Tanigawa T, Iso H: Trends in the incidence of stroke and its subtypes from 1963 to 2018 in Japanese urban and rural communities: The Circulatory Risk in Communities Study (CIRCS). Int J Stroke, 2023; 18: 657-662","DOI":"10.1177\/17474930221135531"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 2006; 355: 549-559","DOI":"10.1056\/NEJMoa061894"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pe\u00f1a JM, Selim MH, Woo D; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; and Stroke Council: Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol, 2023; 43: e404-e442","DOI":"10.1161\/ATV.0000000000000164"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Sanz-Cuesta BE, Saver JL: Lipid-lowering therapy and hemorrhagic stroke risk: comparative meta-analysis of statins and PCSK9 Inhibitors. Stroke, 2021; 52: 3142-3150","DOI":"10.1161\/STROKEAHA.121.034576"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, Zivin JA, Welch KM; SPARCL Investigators: Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology, 2008; 70: 2364-2370","DOI":"10.1212\/01.wnl.0000296277.63350.77"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Lin CK, Chen PY, Wu YY, Wu CC, Chen HJ, Liang CL, Lee YC, Lin CW, Hung CM, Wang HK: Adjunctive Statin Therapy Reduces Mortality After Acute Hemorrhagic Stroke. Risk Manag Healthc Policy, 2021; 14: 177-183","DOI":"10.2147\/RMHP.S290964"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Winardi W, Moi SH, Winardi T, Cheng YW, Chen PY, Lin CK: Nationwide big data analysis of statin use and intracerebral hemorrhage risk in acute ischemic stroke patients in Taiwan. Medicina (Kaunas), 2024; 60: 939","DOI":"10.3390\/medicina60060939"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Ribe AR, Vestergaard CH, Vestergaard M, Pedersen HS, Prior A, Lietzen LW, Brynningsen PK, Fenger-Gr\u00f8n M: Statins and risk of intracerebral hemorrhage in individuals with a history of stroke. Stroke, 2020; 51: 1111-1119","DOI":"10.1161\/STROKEAHA.119.027301"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Kyt\u00f6 V, \u00c5ivo J, Ruuskanen JO: Intensity of statin therapy after ischaemic stroke and long-term outcomes: a nationwide cohort study. Stroke Vasc Neurol, 2025; 10: 142-145","DOI":"10.1136\/svn-2024-003230"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Shin J, Chung JW, Jang HS, Lee J, Hong KS, Bang OY, Kim GM, Seo WK: Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol, 2021; 28: 905-916","DOI":"10.1177\/2047487319830503"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) B\u00e9trisey S, Haller ML, Efthimiou O, Speierer A, Del Giovane C, Moutzouri E, Blum MR, Aujesky D, Rodondi N, Gencer B: Lipid-lowering therapy and risk of hemorrhagic stroke: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc, 2024; 13: e030714","DOI":"10.1161\/JAHA.123.030714"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Kojima I, Ninomiya T, Hata J, Fukuhara M, Hirakawa Y, Mukai N, Yoshida D, Kitazono T, Kiyohara Y: A low ankle brachial index is associated with an increased risk of cardiovascular disease: the Hisayama study. J Atheroscler Thromb, 2014; 21: 966-973","DOI":"10.5551\/jat.22608"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Jansen-Chaparro S, L\u00f3pez-Carmona MD, Cobos-Palacios L, Sanz-C\u00e1novas J, Bernal-L\u00f3pez MR, G\u00f3mez-Huelgas R: Statins and peripheral arterial disease: a narrative review. Front Cardiovasc Med, 2021; 8: 777016","DOI":"10.3389\/fcvm.2021.777016"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, Chandra V, Drachman DE, Eaves JM, Ehrman JK, Evans JN, Getchius TSD, Guti\u00e9rrez JA, Hawkins BM, Hess CN, Ho KJ, Jones WS, Kim ESH, Kinlay S, Kirksey L, Kohlman-Trigoboff D, Long CA, Pollak AW, Sabri SS, Sadwin LB, Secemsky EA, Serhal M, Shishehbor MH, Treat-Jacobson D, Wilkins LR; Peer Review Committee Members: 2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2024; 149: e1313-e1410","DOI":"10.1161\/CIR.0000000000001251"},{"key":"118","unstructured":"118) Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, Bura-Rivi\u00e8re A, De Backer J, Deglise S, Della Corte A, Heiss C, Ka\u0142u\u017cna-Oleksy M, Kurpas D, McEniery CM, Mirault T, Pasquet AA, Pitcher A, Schaubroeck HAI, Schlager O, Sirnes PA, Sprynger MG, Stabile E, Steinbach F, Thielmann M, van Kimmenade RRJ, Venermo M, Rodriguez-Palomares JF; ESC Scientific Document Group: 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J, 2024; 45: 3538-3700"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Belch JJF, Brodmann M, Baumgartner I, Binder CJ, Casula M, Heiss C, Kahan T, Parini P, Poredos P, Catapano AL, Tokg\u00f6zo\u011flu L: Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society\/European Society of Vascular Medicine Joint Statement. Atherosclerosis, 2021; 338: 55-63","DOI":"10.1016\/j.atherosclerosis.2021.09.022"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Abola MTB, Golledge J, Miyata T, Rha SW, Yan BP, Dy TC, Ganzon MSV, Handa PK, Harris S, Zhisheng J, Pinjala R, Robless PA, Yokoi H, Alajar EB, Bermudez-Delos Santos AA, Llanes EJB, Obrado-Nabablit GM, Pesta\u00f1o NS, Punzalan FE, Tumanan-Mendoza B: Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee. J Atheroscler Thromb, 2020; 27: 809-907","DOI":"10.5551\/jat.53660"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121) Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL; REACH Registry Investigators: Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J, 2014; 35: 2864-2872","DOI":"10.1093\/eurheartj\/ehu080"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122) Sagris M, Katsaros I, Giannopoulos S, Rosenberg RD, Altin SE, Rallidis L, Mena-Hurtado C, Armstrong EJ, Kokkinidis DG: Statins and statin intensity in peripheral artery disease. Vasa, 2022; 51: 198-211","DOI":"10.1024\/0301-1526\/a001012"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123) Sofat S, Chen X, Chowdhury MM, Coughlin PA: Effects of statin therapy and dose on cardiovascular and limb outcomes in peripheral arterial disease: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg, 2021; 62: 450-461","DOI":"10.1016\/j.ejvs.2021.05.025"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124) Pastori D, Farcomeni A, Milanese A, Del Sole F, Menichelli D, Hiatt WR, Violi F: Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost, 2020; 120: 866-875","DOI":"10.1055\/s-0040-1709711"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125) Arya S, Khakharia A, Binney ZO, DeMartino RR, Brewster LP, Goodney PP, Wilson PWF: Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation, 2018; 137: 1435-1446","DOI":"10.1161\/CIRCULATIONAHA.117.032361"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126) Kumakura H, Kanai H, Hojo Y, Iwasaki T, Ichikawa S: Long-term survival and fate of the leg in de novo intermittent claudication. Eur Heart J Qual Care Clin Outcomes, 2017; 3: 208-215","DOI":"10.1093\/ehjqcco\/qcw057"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127) Matsuo Y, Kumakura H, Kanai H, Iwasaki T, Ichikawa S: The Geriatric Nutritional Risk Index predicts long-term survival and cardiovascular or limb events in peripheral arterial disease. J Atheroscler Thromb, 2020; 27: 134-143","DOI":"10.5551\/jat.49767"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128) Tomoi Y, Yamaji K, Soga Y, Hiramori S, Ando K: Serum low-density lipoprotein cholesterol level after endovascular therapy in patients with claudication. J Endovasc Ther, 2019; 26: 402-410","DOI":"10.1177\/1526602819836382"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129) Lee JH, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, Hong MK, Jang Y: Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. J Vasc Surg, 2016; 63: 756-763","DOI":"10.1016\/j.jvs.2015.09.059"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130) Clavijo LC, Caro J, Choi J, Caro JA, Tun H, Rowe V, Kumar SR, Shavelle DM, Matthews RV: The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study). Cardiovasc Revasc Med, 2023; 55: 1-5","DOI":"10.1016\/j.carrev.2023.04.020"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131) Sato Y, Uzui H, Morishita T, Fukuoka Y, Hasegawa K, Ikeda H, Tama N, Ishida K, Miyazaki S, Tada H: Effects of PCSK9 inhibitor on favorable limb outcomes in patients with chronic limb-threatening ischemia. J Atheroscler Thromb, 2021; 28: 754-765","DOI":"10.5551\/jat.57653"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132) Fonarow GC, van Hout B, Villa G, Arellano J, Lindgren P: Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiol, 2019; 4: 691-695","DOI":"10.1001\/jamacardio.2019.1647"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133) Ghadimi N, Daroudi R, Shabaninejad H, Goharimehr M, Khodamorzideh D, Kaveh S: Cost-effectiveness of evolocumab in cardiovascular disease: A systematic review. Curr Ther Res Clin Exp, 2024; 101: 100758","DOI":"10.1016\/j.curtheres.2024.100758"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134) Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators: Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med, 2023; 388: 1353-1364","DOI":"10.1056\/NEJMoa2215024"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135) Yamashita S, Kiyosue A, Fujita H, Yokota D, Nakamura Y, Yasuda S: Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial). Circ J, 2025 Mar 28 (Online ahead of print)","DOI":"10.1253\/circj.CJ-25-0089"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136) Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, Alp NJ, Davidson MH: Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med, 2022; 28: 1672-1678","DOI":"10.1038\/s41591-022-01936-7"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137) Harada-Shiba M, Davdison MH, Ditmarsch M, Hsieh A, Wuerdeman E, Kling D, Nield A, Dicklin MR, Nakata A, Sueyoshi A, Kuroyanagi S, Kastelein JJP: Obicetrapib as an adjunct to stable statin therapy in Japanese Subjects: Results from a randomized Phase 2 trial. J Atheroscler Thromb, 2024; 31: 1386-1397","DOI":"10.5551\/jat.64828"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/3\/33_65908\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:39:39Z","timestamp":1772858379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/3\/33_65908\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65908","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"article-number":"65908"}}